# Oliviero Riggio

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 220 papers | 8,539 citations | 52 h-index | 86 g-index |
| 293 ext. papers | 10,143 ext. citations | 4.6 avg, IF | 5.49 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 220 | ESPEN Guidelines on Enteral Nutrition: Liver disease. *Clinical Nutrition*, **2006**, 25, 285-94 | 5.9 | 502 |
| 219 | Incidence and natural history of small esophageal varices in cirrhotic patients. *Journal of Hepatology*, **2003**, 38, 266-72 | 13.4 | 362 |
| 218 | Does malnutrition affect survival in cirrhosis? PINC (Policentrica Italiana Nutrizione Cirrosi). *Hepatology*, **1996**, 23, 1041-6 | 11.2 | 268 |
| 217 | Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. *Hepatology*, **2004**, 40, 629-35 | 11.2 | 257 |
| 216 | Cirrhotic patients are at risk for health care-associated bacterial infections. *Clinical Gastroenterology and Hepatology*, **2010**, 8, 979-85 | 6.9 | 232 |
| 215 | MELD score is better than Child-Pugh score in predicting 3-month survival of patients undergoing transjugular intrahepatic portosystemic shunt. *Journal of Hepatology*, **2002**, 36, 494-500 | 13.4 | 212 |
| 214 | Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts. *American Journal of Gastroenterology*, **2008**, 103, 2738-46 | 0.7 | 183 |
| 213 | Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. *Lancet, The*, **2018**, 391, 2417-2429 | 40 | 176 |
| 212 | Nutritional status: its influence on the outcome of patients undergoing liver transplantation. *Liver International*, **2010**, 30, 208-14 | 7.9 | 170 |
| 211 | Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. *Journal of Hepatology*, **2005**, 42, 674-9 | 13.4 | 161 |
| 210 | Muscle depletion increases the risk of overt and minimal hepatic encephalopathy: results of a prospective study. *Metabolic Brain Disease*, **2013**, 28, 281-4 | 3.9 | 158 |
| 209 | Branched-chain amino acids vs lactulose in the treatment of hepatic coma: a controlled study. *Digestive Diseases and Sciences*, **1982**, 27, 929-35 | 4 | 143 |
| 208 | Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: a randomized multicenter trial. Gruppo Italiano Studio TIPS (G.I.S.T.). *Hepatology*, **1998**, 27, 48-53 | 11.2 | 140 |
| 207 | Basal energy production rate and substrate use in stable cirrhotic patients. *Hepatology*, **1990**, 12, 106-12 | 11.2 | 129 |
| 206 | Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. *Liver International*, **2017**, 37, 694-699 | 7.9 | 128 |
| 205 | High prevalence of spontaneous portal-systemic shunts in persistent hepatic encephalopathy: a case-control study. *Hepatology*, **2005**, 42, 1158-65 | 11.2 | 122 |
| 204 | Polytetrafluoroethylene-covered nitinol stent-graft for transjugular intrahepatic portosystemic shunt creation: 3-year experience. *Radiology*, **2004**, 231, 820-30 | 20.5 | 109 |

| | | | |
|---|---|---|---|
| 203 | Modification of cardiac function in cirrhotic patients with and without ascites. *American Journal of Gastroenterology*, **2000**, 95, 3200-5 | 0.7 | 109 |
| 202 | The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. *Journal of Hepatology*, **2020**, 73, 842-854 | 13.4 | 108 |
| 201 | Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Incidence and risk factors. *Digestive Diseases and Sciences*, **1996**, 41, 578-84 | 4 | 105 |
| 200 | Clinical efficacy of transjugular intrahepatic portosystemic shunt created with covered stents with different diameters: results of a randomized controlled trial. *Journal of Hepatology*, **2010**, 53, 267-72 | 13.4 | 100 |
| 199 | Malnutrition is a risk factor in cirrhotic patients undergoing surgery. *Nutrition*, **2002**, 18, 978-86 | 4.8 | 96 |
| 198 | Sarcopenia Is Risk Factor for Development of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt Placement. *Clinical Gastroenterology and Hepatology*, **2017**, 15, 934-936 | 6.9 | 94 |
| 197 | Short-term oral zinc supplementation does not improve chronic hepatic encephalopathy. Results of a double-blind crossover trial. *Digestive Diseases and Sciences*, **1991**, 36, 1204-8 | 4 | 94 |
| 196 | Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPS. *Gut*, **2011**, 60, 1389-93 | 19.2 | 93 |
| 195 | Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. *Clinics in Liver Disease*, **2012**, 16, 133-46 | 4.6 | 91 |
| 194 | Role of determination of partial pressure of ammonia in cirrhotic patients with and without hepatic encephalopathy. *Journal of Hepatology*, **2003**, 38, 441-6 | 13.4 | 84 |
| 193 | Evidence of persistent cognitive impairment after resolution of overt hepatic encephalopathy. *Clinical Gastroenterology and Hepatology*, **2011**, 9, 181-3 | 6.9 | 81 |
| 192 | Optimal nutritional indexes in chronic liver disease. *Journal of Parenteral and Enteral Nutrition*, **1987**, 11, 130S-134S | 4.2 | 81 |
| 191 | Modifications of cardiac function in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt (TIPS). *American Journal of Gastroenterology*, **2002**, 97, 142-8 | 0.7 | 80 |
| 190 | Effect of lactitol and lactulose administration on the fecal flora in cirrhotic patients. *Journal of Clinical Gastroenterology*, **1990**, 12, 433-6 | 3 | 79 |
| 189 | The natural history of portal hypertensive gastropathy in patients with liver cirrhosis and mild portal hypertension. *American Journal of Gastroenterology*, **2004**, 99, 1959-65 | 0.7 | 76 |
| 188 | Zinc supplementation reduces blood ammonia and increases liver ornithine transcarbamylase activity in experimental cirrhosis. *Hepatology*, **1992**, 16, 785-9 | 11.2 | 75 |
| 187 | Glucose intolerance and insulin resistance in cirrhosis are normalized after liver transplantation. *Hepatology*, **1999**, 30, 649-54 | 11.2 | 73 |
| 186 | Plasma and cerebrospinal fluid amino acid patterns in hepatic encephalopathy. *Digestive Diseases and Sciences*, **1982**, 27, 828-32 | 4 | 73 |

| | | | |
|---|---|---|---|
| 185 | Depression, anxiety and alexithymia symptoms are major determinants of health related quality of life (HRQoL) in cirrhotic patients. *Metabolic Brain Disease*, **2013**, 28, 239-43 | 3.9 | 71 |
| 184 | Low-grade endotoxemia and platelet activation in cirrhosis. *Hepatology*, **2017**, 65, 571-581 | 11.2 | 71 |
| 183 | Improving the inhibitory control task to detect minimal hepatic encephalopathy. *Gastroenterology*, **2010**, 139, 510-8, 518.e1-2 | 13.3 | 71 |
| 182 | The animal naming test: An easy tool for the assessment of hepatic encephalopathy. *Hepatology*, **2017**, 66, 198-208 | 11.2 | 70 |
| 181 | QT interval in patients with non-cirrhotic portal hypertension and in cirrhotic patients treated with transjugular intrahepatic porto-systemic shunt. *Journal of Hepatology*, **2003**, 38, 461-7 | 13.4 | 70 |
| 180 | The chronic use of beta-blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis. *Liver International*, **2015**, 35, 362-9 | 7.9 | 68 |
| 179 | Diagnosis, treatment and survival of patients with hepatorenal syndrome: a survey on daily medical practice. *Journal of Hepatology*, **2011**, 55, 1241-8 | 13.4 | 65 |
| 178 | Efficacy of current guidelines for the treatment of spontaneous bacterial peritonitis in the clinical practice. *World Journal of Gastroenterology*, **2008**, 14, 2757-62 | 5.6 | 65 |
| 177 | Management of refractory hepatic encephalopathy after insertion of TIPS: long-term results of shunt reduction with hourglass-shaped balloon-expandable stent-graft. *American Journal of Roentgenology*, **2009**, 193, 1696-702 | 5.4 | 64 |
| 176 | Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study. *American Journal of Gastroenterology*, **2002**, 97, 1204-10 | 0.7 | 63 |
| 175 | Glucose intolerance in liver cirrhosis. *Metabolism: Clinical and Experimental*, **1982**, 31, 627-34 | 12.7 | 62 |
| 174 | Polytetrafluoroethylene-covered stent grafts for TIPS procedure: 1-year patency and clinical results. *American Journal of Gastroenterology*, **2004**, 99, 280-5 | 0.7 | 61 |
| 173 | The spread of multi drug resistant infections is leading to an increase in the empirical antibiotic treatment failure in cirrhosis: a prospective survey. *PLoS ONE*, **2015**, 10, e0127448 | 3.7 | 60 |
| 172 | Increased risk of cognitive impairment in cirrhotic patients with bacterial infections. *Journal of Hepatology*, **2013**, 59, 243-50 | 13.4 | 54 |
| 171 | Transjugular intrahepatic portosystemic shunt with expanded-polytetrafuoroethylene-covered stents in non-cirrhotic patients with portal cavernoma. *Digestive and Liver Disease*, **2011**, 43, 78-84 | 3.3 | 54 |
| 170 | Validation of automated blood cell counter for the determination of polymorphonuclear cell count in the ascitic fluid of cirrhotic patients with or without spontaneous bacterial peritonitis. *American Journal of Gastroenterology*, **2003**, 98, 1844-8 | 0.7 | 54 |
| 169 | Cost analysis for the prevention of variceal rebleeding: a comparison between transjugular intrahepatic portosystemic shunt and endoscopic sclerotherapy in a selected group of Italian cirrhotic patients. *Hepatology*, **1999**, 29, 1074-7 | 11.2 | 52 |
| 168 | Cardiac dysfunction in cirrhosis is not associated with the severity of liver disease. *European Journal of Internal Medicine*, **2013**, 24, 172-6 | 3.9 | 51 |

| | | | |
|---|---|---|---|
| 167 | The treatment of hepatic encephalopathy. *Metabolic Brain Disease*, **2007**, 22, 389-405 | 3.9 | 50 |
| 166 | Muscle Alterations Are Associated With Minimal and Overt Hepatic Encephalopathy in Patients With Liver Cirrhosis. *Hepatology*, **2019**, 70, 1704-1713 | 11.2 | 49 |
| 165 | Gut-derived endotoxin stimulates factor VIII secretion from endothelial cells. Implications for hypercoagulability in cirrhosis. *Journal of Hepatology*, **2017**, 67, 950-956 | 13.4 | 49 |
| 164 | Total and individual free fatty acid concentrations in liver cirrhosis. *Metabolism: Clinical and Experimental*, **1984**, 33, 646-51 | 12.7 | 49 |
| 163 | Malnutrition is not related to alterations in energy balance in patients with stable liver cirrhosis. *Clinical Nutrition*, **2003**, 22, 553-9 | 5.9 | 48 |
| 162 | An empirical broad spectrum antibiotic therapy in health-care-associated infections improves survival in patients with cirrhosis: A randomized trial. *Hepatology*, **2016**, 63, 1632-9 | 11.2 | 48 |
| 161 | Ongoing Prothrombotic State in the Portal Circulation of Cirrhotic Patients. *Thrombosis and Haemostasis*, **1997**, 77, 044-047 | 7 | 47 |
| 160 | Proton Pump Inhibitors Are Associated With Minimal and Overt Hepatic Encephalopathy and Increased Mortality in Patients With Cirrhosis. *Hepatology*, **2019**, 70, 640-649 | 11.2 | 46 |
| 159 | Vascular disorders of the liver: recommendations from the Italian Association for the Study of the Liver (AISF) ad hoc committee. *Digestive and Liver Disease*, **2011**, 43, 503-14 | 3.3 | 43 |
| 158 | Malabsorption and nutritional abnormalities in patients with liver cirrhosis. *The Italian Journal of Gastroenterology*, **1990**, 22, 118-23 | | 43 |
| 157 | Whole body and regional body composition analysis by dual-energy X-ray absorptiometry in cirrhotic patients. *European Journal of Clinical Nutrition*, **1997**, 51, 810-4 | 5.2 | 42 |
| 156 | Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference. *Digestive and Liver Disease*, **2016**, 48, 455-467 | 3.3 | 41 |
| 155 | Plasma tryptophan levels and anorexia in liver cirrhosis. *International Journal of Eating Disorders*, **1997**, 21, 181-6 | 6.3 | 41 |
| 154 | PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. *Journal of Hepatology*, **2021**, 74, 1097-1108 | 13.4 | 41 |
| 153 | Cognitive Impairment Predicts The Occurrence Of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt. *American Journal of Gastroenterology*, **2016**, 111, 523-8 | 0.7 | 40 |
| 152 | Cognitive dysfunction is associated with poor socioeconomic status in patients with cirrhosis: an international multicenter study. *Clinical Gastroenterology and Hepatology*, **2013**, 11, 1511-6 | 6.9 | 40 |
| 151 | Carbon tetrachloride-induced experimental cirrhosis in the rat: a reappraisal of the model. *European Surgical Research*, **1989**, 21, 280-6 | 1.1 | 38 |
| 150 | A Model for Predicting Development of Overt Hepatic Encephalopathy in Patients With Cirrhosis. *Clinical Gastroenterology and Hepatology*, **2015**, 13, 1346-52 | 6.9 | 36 |

| | | | |
|---|---|---|---|
| 149 | Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). *Digestive and Liver Disease*, **2019**, 51, 190-205 | 3.3 | 36 |
| 148 | Previous overt hepatic encephalopathy rather than minimal hepatic encephalopathy impairs health-related quality of life in cirrhotic patients. *Liver International*, **2011**, 31, 1505-10 | 7.9 | 34 |
| 147 | Lactitol in prevention of recurrent episodes of hepatic encephalopathy in cirrhotic patients with portal-systemic shunt. *Digestive Diseases and Sciences*, **1989**, 34, 823-9 | 4 | 34 |
| 146 | A low muscle mass increases mortality in compensated cirrhotic patients with sepsis. *Liver International*, **2018**, 38, 851-857 | 7.9 | 33 |
| 145 | NADPH oxidase-mediated platelet isoprostane over-production in cirrhotic patients: implication for platelet activation. *Liver International*, **2011**, 31, 1533-40 | 7.9 | 33 |
| 144 | Emerging issues in the use of transjugular intrahepatic portosystemic shunt (TIPS) for management of portal hypertension: time to update the guidelines?. *Digestive and Liver Disease*, **2010**, 42, 462-7 | 3.3 | 33 |
| 143 | A comparison of skinfold anthropometry and dual-energy X-ray absorptiometry for the evaluation of body fat in cirrhotic patients. *Clinical Nutrition*, **1999**, 18, 349-51 | 5.9 | 33 |
| 142 | Peripheral and splanchnic indole and oxindole levels in cirrhotic patients: a study on the pathophysiology of hepatic encephalopathy. *American Journal of Gastroenterology*, **2010**, 105, 1374-81 | 0.7 | 32 |
| 141 | Drug therapy: rifaximin. *Hepatology*, **2010**, 52, 1484-8 | 11.2 | 32 |
| 140 | Effect of glucose and/or branched chain amino acid infusion on plasma amino acid imbalance in chronic liver failure. *Journal of Parenteral and Enteral Nutrition*, **1981**, 5, 414-9 | 4.2 | 32 |
| 139 | A scanning electron microscopic study of liver microcirculation disarrangement in experimental rat cirrhosis. *Hepatology*, **1993**, 17, 477-485 | 11.2 | 31 |
| 138 | Simple tools for complex syndromes: a three-level difficulty test for hepatic encephalopathy. *Digestive and Liver Disease*, **2012**, 44, 957-60 | 3.3 | 30 |
| 137 | Dietary and nutritional indications in hepatic encephalopathy. *Metabolic Brain Disease*, **2009**, 24, 211-21 | 3.9 | 30 |
| 136 | Hepatic encephalopathy: lack of changes of gamma-aminobutyric acid content in plasma and cerebrospinal fluid. *Hepatology*, **1987**, 7, 816-20 | 11.2 | 30 |
| 135 | Predictive factors of outcome after liver transplantation in patients with cirrhosis and hepatocellular carcinoma. *Transplantation Proceedings*, **2005**, 37, 2535-40 | 1.1 | 29 |
| 134 | Quality of life in patients with minimal hepatic encephalopathy. *World Journal of Gastroenterology*, **2018**, 24, 5446-5453 | 5.6 | 28 |
| 133 | The burden of minimal hepatic encephalopathy: from diagnosis to therapeutic strategies. *Annals of Gastroenterology*, **2018**, 31, 151-164 | 2.2 | 28 |
| 132 | Endoscopic screening for esophageal varices in cirrhotic patients. *Hepatology*, **2002**, 35, 501-2 | 11.2 | 27 |

| | | | |
|---|---|---|---|
| 131 | The modification of quantity and quality of muscle mass improves the cognitive impairment after TIPS. *Liver International*, **2019**, 39, 871-877 | 7.9 | 26 |
| 130 | Natural history of patients with non cirrhotic portal hypertension: Comparison with patients with compensated cirrhosis. *Digestive and Liver Disease*, **2018**, 50, 839-844 | 3.3 | 26 |
| 129 | Effect of sodium benzoate on blood ammonia response to oral glutamine challenge in cirrhotic patients: a note of caution. *American Journal of Gastroenterology*, **2000**, 95, 3574-8 | 0.7 | 26 |
| 128 | Hepatic encephalopathy expands the predictivity of model for end-stage liver disease in liver transplant setting: Evidence by means of 2 independent cohorts. *Liver Transplantation*, **2016**, 22, 1333-42 | 4.5 | 24 |
| 127 | Rifaximin therapy and hepatic encephalopathy: Pros and cons. *World Journal of Gastrointestinal Pharmacology and Therapeutics*, **2012**, 3, 62-7 | 3 | 24 |
| 126 | A simplified psychometric evaluation for the diagnosis of minimal hepatic encephalopathy. *Clinical Gastroenterology and Hepatology*, **2011**, 9, 613-6.e1 | 6.9 | 22 |
| 125 | Nutritional status and liver transplantation. *Journal of Clinical and Experimental Hepatology*, **2011**, 1, 190-8 | 4.1 | 22 |
| 124 | Modification of splenic stiffness on acoustic radiation force impulse parallels the variation of portal pressure induced by transjugular intrahepatic portosystemic shunt. *Journal of Gastroenterology and Hepatology (Australia)*, **2018**, 33, 704-709 | 4 | 20 |
| 123 | Survival at 2 years among liver cirrhotic patients is influenced by left atrial volume and left ventricular mass. *Liver International*, **2017**, 37, 700-706 | 7.9 | 20 |
| 122 | Effect of lactitol on blood ammonia response to oral glutamine challenge in cirrhotic patients: evidence for an effect of nonabsorbable disaccharides on small intestine ammonia generation. *American Journal of Gastroenterology*, **1999**, 94, 3323-7 | 0.7 | 20 |
| 121 | Improvement of nutritional status in malnourished cirrhotic patients one year after liver transplantation. *European E-journal of Clinical Nutrition and Metabolism*, **2011**, 6, e142-e147 | | 19 |
| 120 | No effect of albumin infusion on the prevention of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. *Metabolic Brain Disease*, **2016**, 31, 1275-1281 | 3.9 | 17 |
| 119 | Idiopathic non cirrhotic portal hypertension and spleno-portal axis abnormalities in patients with severe primary antibody deficiencies. *Journal of Immunology Research*, **2014**, 2014, 672458 | 4.5 | 17 |
| 118 | Liver metabolic zonation and hepatic microcirculation in carbon tetrachloride-induced experimental cirrhosis. *Digestive Diseases and Sciences*, **1997**, 42, 167-77 | 4 | 17 |
| 117 | Early postprandial energy expenditure and macronutrient use after a mixed meal in cirrhotic patients. *Journal of Parenteral and Enteral Nutrition*, **1992**, 16, 445-50 | 4.2 | 17 |
| 116 | Idiopathic noncirrhotic portal hypertension: current perspectives. *Hepatic Medicine: Evidence and Research*, **2016**, 8, 81-8 | 3.4 | 17 |
| 115 | Effect of blood ammonia elevation following oral glutamine load on the psychometric performance of cirrhotic patients. *Metabolic Brain Disease*, **2003**, 18, 27-35 | 3.9 | 16 |
| 114 | The effect of lactulose and lactitol administration on fecal fat excretion in patients with liver cirrhosis. *Journal of Clinical Gastroenterology*, **1992**, 15, 125-7 | 3 | 16 |

| | | | |
|---|---|---|---|
| 113 | Aminoacid imbalance and malnutrition in liver cirrhosis. *Clinical Nutrition*, **1985**, 4, 249-53 | 5.9 | 16 |
| 112 | AISF-SIMTI Position Paper: The appropriate use of albumin in patients with liver cirrhosis. *Digestive and Liver Disease*, **2016**, 48, 4-15 | 3.3 | 15 |
| 111 | Phagocytosis of gadolinium chloride or zymosan induces simultaneous upregulation of hepcidin- and downregulation of hemojuvelin- and Fpn-1-gene expression in murine liver. *Laboratory Investigation*, **2009**, 89, 1252-60 | 5.9 | 15 |
| 110 | Increased nonoxidative glucose metabolism in idiopathic reactive hypoglycemia. *Metabolism: Clinical and Experimental*, **1996**, 45, 606-10 | 12.7 | 15 |
| 109 | Accuracy of the automated cell counters for management of spontaneous bacterial peritonitis. *World Journal of Gastroenterology*, **2008**, 14, 5689-94 | 5.6 | 15 |
| 108 | Sarcopenia and cognitive impairment in liver cirrhosis: A viewpoint on the clinical impact of minimal hepatic encephalopathy. *World Journal of Gastroenterology*, **2019**, 25, 5257-5265 | 5.6 | 15 |
| 107 | Spontaneous porto-systemic shunts in liver cirrhosis: Clinical and therapeutical aspects. *World Journal of Gastroenterology*, **2020**, 26, 1726-1732 | 5.6 | 15 |
| 106 | Hepatic encephalopathy therapy: An overview. *World Journal of Gastrointestinal Pharmacology and Therapeutics*, **2010**, 1, 54-63 | 3 | 15 |
| 105 | Hepatic Encephalopathy Is Associated with Persistent Learning Impairments Despite Adequate Medical Treatment: A Multicenter, International Study. *Digestive Diseases and Sciences*, **2017**, 62, 794-800 | 4 | 13 |
| 104 | Hepatic encephalopathy in patients with non-cirrhotic portal hypertension: Description, prevalence and risk factors. *Digestive and Liver Disease*, **2016**, 48, 1072-7 | 3.3 | 13 |
| 103 | Impaired nonoxidative glucose metabolism in patients with liver cirrhosis: effects of two insulin doses. *Metabolism: Clinical and Experimental*, **1997**, 46, 840-3 | 12.7 | 13 |
| 102 | Zinc, ammonia, and Helicobacter pylori infection in liver cirrhosis. *Digestive and Liver Disease*, **2000**, 32, 836-8 | 3.3 | 13 |
| 101 | Zinc and other trace elements in liver cirrhosis. *The Italian Journal of Gastroenterology*, **1991**, 23, 386-91 | | 13 |
| 100 | Radiological Intervention for Shunt Related Encephalopathy. *Journal of Clinical and Experimental Hepatology*, **2018**, 8, 452-459 | 4.1 | 12 |
| 99 | Fatty acid composition of adipose tissue in patients with chronic liver disease. *Journal of Hepatology*, **1986**, 3, 104-10 | 13.4 | 11 |
| 98 | A scanning electron microscopic study of liver microcirculation disarrangement in experimental rat cirrhosis. *Hepatology*, **1993**, 17, 477-85 | 11.2 | 11 |
| 97 | On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites. *Journal of Hepatology*, **2021**, 74, 340-349 | 13.4 | 11 |
| 96 | Clinical practice guidelines for the management of cirrhotic patients with ascites. Committee on Ascites of the Italian Association for the Study of the Liver. *Italian Journal of Gastroenterology and Hepatology*, **1999**, 31, 626-34 | | 11 |

| | | | |
|---|---|---|---|
| 95 | D-Lactic acidosis 25 years after bariatric surgery due to Salmonella enteritidis. *Nutrition*, **2012**, 28, 108-11 | 4.8 | 10 |
| 94 | Impaired hepatic handling and processing of lysophosphatidylcholine in rats with liver cirrhosis. *Gastroenterology*, **1991**, 101, 228-37 | 13.3 | 10 |
| 93 | Lactitol in the treatment of chronic hepatic encephalopathy--a randomized cross-over comparison with lactulose. *Hepato-Gastroenterology*, **1990**, 37, 524-7 | | 10 |
| 92 | Hepatitis C virus eradication with directly acting antivirals improves health-related quality of life and psychological symptoms. *World Journal of Gastroenterology*, **2019**, 25, 6928-6938 | 5.6 | 10 |
| 91 | The additive value of sarcopenia, myosteatosis and hepatic encephalopathy in the predictivity of model for end-stage liver disease. *Digestive and Liver Disease*, **2019**, 51, 1508-1512 | 3.3 | 9 |
| 90 | Polyunsaturated fatty acids balance affects platelet NOX2 activity in patients with liver cirrhosis. *Digestive and Liver Disease*, **2014**, 46, 632-8 | 3.3 | 9 |
| 89 | Small hepatic veins Budd-Chiari syndrome. *Journal of Thrombosis and Thrombolysis*, **2014**, 37, 536-9 | 5.1 | 9 |
| 88 | Resistance to insulin suppression of plasma free fatty acids in liver cirrhosis. *Journal of Endocrinological Investigation*, **1990**, 13, 787-95 | 5.2 | 9 |
| 87 | Nutritional status in liver cirrhosis. *The Italian Journal of Gastroenterology*, **1993**, 25, 400-1 | | 9 |
| 86 | Hepatic Encephalopathy: Diagnosis and Management. *Journal of Translational Internal Medicine*, **2020**, 8, 210-219 | 3 | 9 |
| 85 | Prevalence and impact of sarcopenia in non-cirrhotic portal hypertension. *Liver International*, **2019**, 39, 1937-1942 | 7.9 | 8 |
| 84 | Management of Hepatic Encephalopathy Not Responsive to First-Line Treatments. *Current Treatment Options in Gastroenterology*, **2018**, 16, 253-259 | 2.5 | 8 |
| 83 | <emph type="2">Intractable Hepatic Encephalopathy After Tips with Polytetrafluoroethylene-covered Stent-Graft</emph&gt. *Scandinavian Journal of Gastroenterology*, **2003**, 38, 570-572 | 2.4 | 8 |
| 82 | Increased energy expenditure in cirrhotic patients with hepatocellular carcinoma. *Nutrition*, **1992**, 8, 321-5 | 4.8 | 8 |
| 81 | The hepatic microcirculation in experimental cirrhosis. A scanning electron microscopy study of microcorrosion casts. *Scanning Microscopy*, **1991**, 5, 495-502; discussion 502-3 | | 8 |
| 80 | Use of the stable isotope 65Cu test for the screening of Wilson's disease in a family with two affected members. *Italian Journal of Gastroenterology and Hepatology*, **1998**, 30, 270-5 | | 8 |
| 79 | Clinical management of type C hepatic encephalopathy. *United European Gastroenterology Journal*, **2020**, 8, 536-543 | 5.3 | 7 |
| 78 | Hepatocellular carcinoma in cirrhotic patients with transjugular intrahepatic portosystemic shunt: a retrospective case-control study. *Digestive and Liver Disease*, **2014**, 46, 726-30 | 3.3 | 7 |

| | | | |
|---|---|---|---|
| 77 | Is spontaneous bacterial peritonitis an inducer of vasopressin analogue side-effects? A case report. *Digestive and Liver Disease*, **2003**, 35, 503-6 | 3.3 | 7 |
| 76 | Clotting Activation after Transjugular Intrahepatic Portosystemic Stent Shunt. *Thrombosis and Haemostasis*, **1999**, 81, 711-714 | 7 | 7 |
| 75 | Insulin and glucagon levels in fulminant hepatic failure in man. *Digestive Diseases and Sciences*, **1991** , 36, 801-8 | 4 | 7 |
| 74 | Relevance of Spontaneous Portosystemic Shunts Detected with CT in Patients with Cirrhosis. *Radiology*, **2021**, 299, 133-140 | 20.5 | 7 |
| 73 | Branched-Chain Amino Acids in the Treatment of Severe Hepatic Encephalopathy **1984**, 335-344 | | 7 |
| 72 | Incidence of portal hypertension in patients exposed to oxaliplatin. *Digestive and Liver Disease*, **2019**, 51, 1348-1350 | 3.3 | 6 |
| 71 | Reply to Dr. Andus letter. *Clinical Nutrition*, **2007**, 26, 273-274 | 5.9 | 6 |
| 70 | Clinical nutrition practice in Italian Gastroenterology Units. *Digestive and Liver Disease*, **2000**, 32, 473-9 | 3.3 | 6 |
| 69 | Ticlopidine-induced cholestasis. *European Journal of Gastroenterology and Hepatology*, **1994**, 6, 943-950 | 2.2 | 6 |
| 68 | Is the blood-brain barrier really intact in portal-systemic encephalopathy?. *Lancet, The*, **1981**, 1, 1367 | 40 | 6 |
| 67 | Circadian rhythmicity of plasma amino acid variations in healthy subjects. *Recenti Progressi in Medicina*, **1989**, 80, 591-3 | 0.7 | 6 |
| 66 | Zinc supplementation in experimental liver cirrhosis: a morphological, structural and ultrastructural study. *International Journal of Experimental Pathology*, **1993**, 74, 463-9 | 2.8 | 6 |
| 65 | Causes and Management of Non-cirrhotic Portal Hypertension . *Current Gastroenterology Reports*, **2020**, 22, 56 | 5 | 6 |
| 64 | How to Design a Multicenter Clinical Trial in Hepatic Encephalopathy. *Journal of Clinical and Experimental Hepatology*, **2019**, 9, 137-145 | 4.1 | 6 |
| 63 | The improvement in body composition including subcutaneous and visceral fat reduces ammonia and hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. *Liver International* , **2021**, | 7.9 | 6 |
| 62 | PS-083-Serum albumin concentration as guide for long-term albumin treatment in patients with cirrhosis and uncomplicated ascites: Lessons from the ANSWER study. *Journal of Hepatology*, **2019**, 70, e53 | 13.4 | 5 |
| 61 | Intravascular hemolysis and transjugular intrahepatic portosystemic stent shunt. *Journal of Hepatology*, **1994**, 20, 152-3 | 13.4 | 5 |
| 60 | Portal Hypertension Related to Schistosomiasis Treated With a Transjugular Intrahepatic Portosystemic Shunt. *Journal of Clinical Gastroenterology*, **2016**, 50, 608-10 | 3 | 5 |

| | | | |
|---|---|---|---|
| 59 | Portal Hypertension and Ascites: Patient-and Population-centered Clinical Practice Guidelines by the Italian Association for the Study of the Liver (AISF). *Digestive and Liver Disease*, **2021**, 53, 1089-1104 | 3.3 | 5 |
| 58 | A cost analysis of a broad-spectrum antibiotic therapy in the empirical treatment of health care-associated infections in cirrhotic patients. *ClinicoEconomics and Outcomes Research*, **2017**, 9, 385-390 | 1.7 | 4 |
| 57 | P473 BACTERIAL INFECTIONS IN CIRRHOTIC PATIENTS: RISK FACTORS AND RATE OF FAILURE OF THE EMPIRICAL ANTIBIOTIC THERAPY. *Journal of Hepatology*, **2014**, 60, S227 | 13.4 | 4 |
| 56 | Can an incomplete stent expansion modulate the effects of TIPS?. *Journal of Gastroenterology*, **2010**, 45, 346-7; author reply 348 | 6.9 | 4 |
| 55 | Is hyperammonemia really the true cause of altered neuropsychology, brain MR spectroscopy and magnetization transfer after an oral amino acid load in cirrhosis?. *Hepatology*, **2003**, 38, 777; author reply 778 | 11.2 | 4 |
| 54 | Gut liver muscle brain axis: a comprehensive viewpoint on prognosis in cirrhosis.. *Journal of Hepatology*, **2022**, | 13.4 | 4 |
| 53 | Is porto sinusoidal vascular disease to be actively searched in patients with portal vein thrombosis?. *World Journal of Hepatology*, **2019**, 11, 613-618 | 3.4 | 4 |
| 52 | Long-term use of human albumin for the treatment of ascites in patients with hepatic cirrhosis: The interim analysis of the ANSWER study. *Digestive and Liver Disease*, **2015**, 47, e6 | 3.3 | 3 |
| 51 | Albumin infusion in cirrhotic patients with infections other than spontaneous bacterial peritonitis: End of the story?. *Journal of Hepatology*, **2015**, 63, 767-8 | 13.4 | 3 |
| 50 | Management of hepatic encephalopathy as an inpatient. *Clinical Liver Disease*, **2015**, 5, 79-82 | 2.2 | 3 |
| 49 | Emerging drugs for hepatic encephalopathy. *Expert Opinion on Emerging Drugs*, **2009**, 14, 537-49 | 3.7 | 3 |
| 48 | Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: still a major problem. *Hepatology*, **2010**, 51, 2237-8 | 11.2 | 3 |
| 47 | TIPS versus paracentesis in the treatment of refractory ascites: Preliminary results of a randomized controlled trial. *Gastroenterology*, **2000**, 118, A980 | 13.3 | 3 |
| 46 | Nonabsorbable disaccharides plus neomycin in hepatic encephalopathy: do they enhance each other?. *Hepatology*, **1990**, 12, 368-70 | 11.2 | 3 |
| 45 | Simultaneous radioenzymatic determination of phenylethylamine, phenylethanolamine, tyramine and octopamine in plasma of patients with hepatic encephalopathy. *Clinical Biochemistry*, **1981**, 14, 187-90 | 2.5 | 3 |
| 44 | Low Interleukin-22 Binding Protein Is Associated With High Mortality in Alcoholic Hepatitis and Modulates Interleukin-22 Receptor Expression. *Clinical and Translational Gastroenterology*, **2020**, 11, e00197 | 4.2 | 3 |
| 43 | Risk of falls in patients with cirrhosis evaluated by timed up and go test: Does muscle or brain matter more?. *Digestive and Liver Disease*, **2021**, | 3.3 | 3 |
| 42 | Letter to the Editor: Liver Stiffness in Noncirrhotic Portal Hypertension: The Devil Is in the Diagnosis. *Hepatology*, **2019**, 70, 444-445 | 11.2 | 3 |

| | | | |
|---|---|---|---|
| 41 | Long-term albumin administration in patients with cirrhosis and uncomplicated ascites: the use of serum albumin concentration for personalizing treatment. *Digestive and Liver Disease*, **2019**, 51, e9 | 3.3 | 2 |
| 40 | Interaction between infection and hepatic encephalopathy. *Journal of Hepatology*, **2015**, 62, 746-7 | 13.4 | 2 |
| 39 | TIPS for patients awaiting orthotopic liver transplantation. *Liver Transplantation*, **2003**, 9, 999-1000 | 4.5 | 2 |
| 38 | Ammonia and the Muscle: An Emerging Point of View on Hepatic Encephalopathy.. *Journal of Clinical Medicine*, **2022**, 11, | 5.1 | 2 |
| 37 | Does malnutrition affect survival in cirrhosis? **1996**, 23, 1041 | | 2 |
| 36 | Proton pump inhibitors increase the risk of minimal and overt hepatic encephalopathy and they are associated with high mortality in cirrhotic patients. *Journal of Hepatology*, **2018**, 68, S732-S733 | 13.4 | 2 |
| 35 | Neurological and psychiatric effects of hepatitis C virus infection. *World Journal of Gastroenterology* , **2021**, 27, 4846-4861 | 5.6 | 2 |
| 34 | Clotting activation after transjugular intrahepatic portosystemic stent shunt. *Thrombosis and Haemostasis*, **1999**, 81, 711-4 | 7 | 2 |
| 33 | Intractable hepatic encephalopathy after tips with polytetrafluoroethylene-covered stent-graft. *Scandinavian Journal of Gastroenterology*, **2003**, 38, 570-2 | 2.4 | 2 |
| 32 | Reply. *Hepatology*, **2019**, 70, 762-763 | 11.2 | 1 |
| 31 | Small-for-flow liver failure after extended hepatectomy: hot questions and an update. *Gastroenterology Insights*, **2017**, 8, | 2.1 | 1 |
| 30 | May sarcopenia and/or hepatic encephalopathy improve the predictivity of model for end-stage liver disease?. *Journal of Hepatology*, **2018**, 68, 1324-1325 | 13.4 | 1 |
| 29 | Prediction of hepatic encephalopathy: Why disregard well-known risk factors?. *Hepatology*, **2018**, 67, 1637 | 11.2 | 1 |
| 28 | Do we really need alternatives to polymorphonuclear cells counting in ascitic fluid?. *Gastroenterology*, **2009**, 136, 728-9; author reply 729 | 13.3 | 1 |
| 27 | Hepatic encephalopathy: you should only comment on what you have actually measured. *Journal of Gastroenterology*, **2010**, 45, 342-3; author reply 344-5 | 6.9 | 1 |
| 26 | Composition of free fatty acids and adipose tissue triglycerides in portacaval shunted rats. *European Surgical Research*, **1987**, 19, 151-8 | 1.1 | 1 |
| 25 | Macronutrient oxidation in liver disease. *The Italian Journal of Gastroenterology*, **1993**, 25, 272-5 | | 1 |
| 24 | Nutrition and Hepatic Encephalopathy **2012**, 199-209 | | 1 |

| | | | |
|---|---|---|---|
| 23 | TIPS: Refractory Ascites and Encephalopathy. *Medical Radiology*, **2000**, 297-303 | 0.2 | 1 |
| 22 | A scanning electron microscopic study of liver microcirculation disarrangement in experimental rat cirrhosis **1993**, 17, 477 | | 1 |
| 21 | P: 25 Muscle Alterations Are Associated With Minimal and Overt Hepatic Encephalopathy in Patients With Liver Cirrhosis. *American Journal of Gastroenterology*, **2019**, 114, S13-S13 | 0.7 | 1 |
| 20 | Session 1: Definition of Key Events Last Attempt?11-39 | | 1 |
| 19 | Nutrition Assessment and Management in Patients with Cirrhosis and Cognitive Impairment: A Comprehensive Review of Literature. *Journal of Clinical Medicine*, **2022**, 11, 2842 | 5.1 | 1 |
| 18 | Erectile dysfunction in patients with liver cirrhosis. *Digestive and Liver Disease*, **2019**, 51, 856-857 | 3.3 | 0 |
| 17 | Identifying Patients at High Risk of Developing Non-Cirrhotic Portal Hypertension. *Hepatic Medicine: Evidence and Research*, **2021**, 13, 105-111 | 3.4 | 0 |
| 16 | Small hepatic veins Budd-Chiari syndrome and paroxysmal nocturnal hemoglobinuria - The association of two rare entities: a case report. *Pathologica*, **2020**, 112, 102-104 | 1.9 | 0 |
| 15 | Beta-blockers in patients with cirrhosis and infections: don't blame too soon!. *Liver International*, **2015**, 35, 1778-9 | 7.9 | |
| 14 | Long-term albumin administration is not futile in patients with cirrhosis and uncomplicated ascites not normalizing serum albumin concentration with treatment. *Journal of Hepatology*, **2020**, 73, S738 | 13.4 | |
| 13 | Reply: To PMID 23707462. *Clinical Gastroenterology and Hepatology*, **2014**, 12, 707-8 | 6.9 | |
| 12 | Response to Drs. Piscaglia et al.. *American Journal of Gastroenterology*, **2001**, 96, 2504-2505 | 0.7 | |
| 11 | Iron reduction and sustained response to interferon- therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study. *American Journal of Gastroenterology*, **2002**, 97, 1204-1210 | 0.7 | |
| 10 | Hyperdynamic circulation after tips implantation: its effects on neurohumoral system. *Journal of Hepatology*, **2002**, 36, 201-202 | 13.4 | |
| 9 | Prevalence of chronic liver disease in northern Italy. *Hepatology*, **1996**, 23, 1710-2 | 11.2 | |
| 8 | The Pros and the Cons of the Amino Acid Neurotransmitter Hypothesis **1984**, 460-471 | | |
| 7 | Letter to the editor: Episodic-precipitant induced hepatic encephalopathy treatment: look at new and old precipitants!. *Hepatology*, **2021**, | 11.2 | |
| 6 | Prevention of hepatic encephalopathy after porto-systemic shunt551-554 | | |

| | | |
|---|---|---|
| 5 | JAK2 (V617F) Mutation Levels and Marrow Fibrosis in Patients Affected by Budd-Chiari Syndrome and Non-Cirrhotic Extra-Hepatic Portal Vein Obstruction.. *Blood*, **2007**, 110, 4652-4652 | 2.2 |
| 4 | Effects of Branched Chain Amino Acids on Biochemical Variables and Clinical Symptoms of Hepatic Encephalopathy* **1983**, 400-411 | |
| 3 | P: 26 The Modification of Quantity and Quality of Muscle Mass Improves the Cognitive Impairment After TIPS. *American Journal of Gastroenterology*, **2019**, 114, S14-S14 | 0.7 |
| 2 | Episodic Precipitant-induced Hepatic Encephalopathy Treatment: The Ideal Trial Is Still Lacking.. *Journal of Clinical Gastroenterology*, **2022**, 56, 192-193 | 3 |
| 1 | The application of Pancreatitis Activity Score System in clinical practice: an Italian experience.. *European Journal of Gastroenterology and Hepatology*, **2022**, 34, 724-725 | 2.2 |